 Shares of Poseida Therapeutics Inc. PSTX, 1.22 were up 9.6 in premarket trading on Tuesday after the company said it signed a research and licensing agreement with Takeda Pharmaceutical Co. Ltd. 4502, -0.12 to study and commercialize up to eight gene therapies. 